Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818670 | 1.00 | F10 (0.58) | F10 | |
| SCHEMBL3810905 | 1.00 | F10 (0.58) | F10 | |
| SCHEMBL3832193 | 0.89 | F10 (0.61) | F10 | |
| SCHEMBL14145750 | 0.85 | F10 (0.53) | F10 | |
| SCHEMBL4606006 | 0.78 | F10 (0.56) | F10 | |
| SCHEMBL4604880 | 0.78 | F10 (0.56) | F10 | |
| SCHEMBL4607788 | 0.78 | F10 (0.56) | F10 | |
| SCHEMBL3829116 | 0.77 | F10 (0.65) | F10 | |
| SCHEMBL3832114 | 0.77 | F10 (0.64) | F10 | |
| SCHEMBL5830819 | 0.76 | F10 (0.59) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171773-A1 | A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc | PFIZER INC | 2008-07-17 | — | — | US | disclosed |
| US-20080171773-A1 | A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc | PFIZER INC | 2008-07-17 | — | — | US | disclosed |
| WO-2008065503-A1 | (R) -5-METHYL-4, 5-DIHYDRO- PYRAZOLE-1, 5-DICARBOXYLIC ACID 1- [ ( 4 -CHLOROPHENYL) AMIDE 5-{ [2-FLUORO-4- (2-OXO-2H-PYRIDIN-1-YL) -PHENYL]AMIDE) AS A FACTOR XA INHIBITOR | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171773-A1 | A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc | F2, PLG, PLAT | F10 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.